Literature DB >> 9819791

Role of hepatocyte growth factor and its receptor c-met in multiple myeloma.

C Seidel1, M Børset, H Hjorth-Hansen, A Sundan, A Waage.   

Abstract

Multiple myeloma is characterised by the clonal expansion of malignant plasma cells. Recently, we reported that a new cytokine, hepatocyte growth factor (HGF), and its receptor c-met are related to this disease. Here we review the observations that associate HGF with myeloma. Malignant plasma cells produce HGF and express the receptor c-met. Many patients have elevated HGF levels, which is unfavourable both in terms of survival and response to treatment. Possible biological roles of HGF in this disease are discussed, with special focus on bone homeostasis and its binding to heparan sulphate proteoglycans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9819791     DOI: 10.1007/BF02821933

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  71 in total

1.  Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia.

Authors:  H Hjorth-Hansen; C Seidel; J Lamvik; M Börset; A Sundan; A Waage
Journal:  Eur J Haematol       Date:  1999-02       Impact factor: 2.997

2.  Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group.

Authors:  C Seidel; M Børset; I Turesson; N Abildgaard; A Sundan; A Waage
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

3.  Met expression and sarcoma tumorigenicity.

Authors:  S Rong; M Jeffers; J H Resau; I Tsarfaty; M Oskarsson; G F Vande Woude
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

4.  Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma.

Authors:  S E Salmon; B A Smith
Journal:  J Clin Invest       Date:  1970-06       Impact factor: 14.808

5.  Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor.

Authors:  Y Uehara; O Minowa; C Mori; K Shiota; J Kuno; T Noda; N Kitamura
Journal:  Nature       Date:  1995-02-23       Impact factor: 49.962

6.  Hepatocyte growth factor/scatter factor has insulinotropic activity in human fetal pancreatic cells.

Authors:  T Otonkoski; G M Beattie; J S Rubin; A D Lopez; A Baird; A Hayek
Journal:  Diabetes       Date:  1994-07       Impact factor: 9.461

7.  Heparin modulates the receptor-binding and mitogenic activity of hepatocyte growth factor on hepatocytes.

Authors:  D Naka; T Ishii; T Shimomura; T Hishida; H Hara
Journal:  Exp Cell Res       Date:  1993-12       Impact factor: 3.905

8.  Hepatocyte growth factor accelerates the wound repair of cultured gastric mucosal cells.

Authors:  S Watanabe; M Hirose; X E Wang; K Maehiro; T Murai; O Kobayashi; A Nagahara; N Sato
Journal:  Biochem Biophys Res Commun       Date:  1994-03-30       Impact factor: 3.575

9.  Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity.

Authors:  T F Zioncheck; L Richardson; J Liu; L Chang; K L King; G L Bennett; P Fügedi; S M Chamow; R H Schwall; R J Stack
Journal:  J Biol Chem       Date:  1995-07-14       Impact factor: 5.157

10.  Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors.

Authors:  F Galimi; G P Bagnara; L Bonsi; E Cottone; A Follenzi; A Simeone; P M Comoglio
Journal:  J Cell Biol       Date:  1994-12       Impact factor: 10.539

View more
  4 in total

1.  Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.

Authors:  Liem M Phan; Enrique Fuentes-Mattei; Weixin Wu; Guermarie Velazquez-Torres; Kanishka Sircar; Christopher G Wood; Tao Hai; Camilo Jimenez; Gilbert J Cote; Levent Ozsari; Marie-Claude Hofmann; Siyuan Zheng; Roeland Verhaak; Lance Pagliaro; Maria Angelica Cortez; Mong-Hong Lee; Sai-Ching J Yeung; Mouhammed Amir Habra
Journal:  Cancer Res       Date:  2015-08-17       Impact factor: 12.701

Review 2.  Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.

Authors:  V Finisguerra; H Prenen; M Mazzone
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

3.  Targeting MET transcription as a therapeutic strategy in multiple myeloma.

Authors:  Cornel J Phillip; Christine M Stellrecht; Ramadevi Nimmanapalli; Varsha Gandhi
Journal:  Cancer Chemother Pharmacol       Date:  2008-05-29       Impact factor: 3.333

Review 4.  MET: a promising anticancer therapeutic target.

Authors:  Solange Peters; Alex A Adjei
Journal:  Nat Rev Clin Oncol       Date:  2012-05-08       Impact factor: 66.675

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.